Tempest Therapeutics
TPST
22 hedge funds and large institutions have $4.86M invested in Tempest Therapeutics in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
232% more capital inflows, than outflows
Capital inflows: $1.98M | Capital outflows: $596K
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
29% more funds holding
Funds holding: 17 → 22 (+5)
3.57% more ownership
Funds ownership: 29.45% → 33.02% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$786K |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$425K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$197K |
| 4 |
EcoR1 Capital
San Francisco,
California
|
+$178K |
| 5 |
Renaissance Technologies
New York
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rock Springs Capital Management
Baltimore,
Maryland
|
-$556K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25.7K |
| 3 |
Millennium Management
New York
|
-$12.5K |
| 4 |
JP Morgan Chase
New York
|
-$1K |
| 5 |
Morgan Stanley
New York
|
-$50 |
TPST Hedge Fund Activity: Q2 2023 in Review
22 of the 6,388 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2023, worth a combined $4.86M — down 33% from $7.21M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TPST positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $786K. The largest seller was Rock Springs Capital Management, cutting an estimated $556K.
- 22 institutional investors held Tempest Therapeutics (TPST) as of Q2 2023, up from 17 in Q1 2023.
- Funds reported $4.86M of Tempest Therapeutics stock for Q2 2023, down 33% quarter-over-quarter.
- 7 funds opened new Tempest Therapeutics positions in Q2 2023 and 2 closed out, a net change of +5 holders.
- The largest Tempest Therapeutics buyer in Q2 2023 was AIGH Capital Management, an estimated $786K added.
- The largest Tempest Therapeutics seller in Q2 2023 was Rock Springs Capital Management, an estimated $556K sold.
Based on aggregated 13F filings for Q2 2023.